Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Revisits Old Issues For Novartis' COPD Drug Indacaterol At Panel Review

This article was originally published in The Pink Sheet Daily

Executive Summary

The Pulmonary-Allergy Drugs Advisory Committee is being asked whether safety and efficacy have been established for two doses of the chronic obstructive pulmonary disease treatment Arcapta, the same problem that caused an earlier "complete response" letter.

You may also be interested in...



Arcapta Quality Of Life Data For High Dose Cannot Overcome Efficacy Questions

FDA's Pulmonary-Allergy Drugs Advisory Committee endorses approval of the 75 mcg dose of indacaterol but recommends against approval of Novartis' preferred 150 mcg dose of the chronic obstructive pulmonary disease drug.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel